Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
The company’s largest center for medical device applications, serving the entire Asian market
Subscribe To Our Newsletter & Stay Updated